Abstract Background: Human androgen receptor (AR) functions as a steroid-hormone activated transcription factor. The receptor binds to its ligand (testosterone or dihydrotestosterone) and is translocated to the nucleus to stimulate the transcription of androgen responsive genes. Mutations in the ligand binding domain (LBD) impair the receptor activity and play a crucial role in the development and progression of prostate cancer (PCa).
Introduction
Prostate cancer is the sixth leading cause of cancer-related deaths among men [1] . Prostate cancer cells usually acquire a large number of genetic alterations including point mutations, deletions, amplifications and translocations. Also, a wide range of epigenetic modifications was reported, such as changes in the acetylation and/or methylation patterns in addition to chromatin remodeling [2, 3] . This type of cancer develops through a gradual progression through which the benign prostatic epithelial cells progress to prostatic intraepithelial neoplasia (PIN), invasive adenocarcinoma, distant metastatic disease and androgen refractory metastatic disease [4] . This transformation is characterized by several diagnostic nuclear morphological features, such as nuclear and nucleolar enlargement and alterations in chromatin structure [5] .
The dependence of prostate cancer on androgen stimulation was described few decades ago [6] . Androgens (testosterone or dihydrotestosterone) bind to the androgen receptors (AR) and the liganded receptor is translocated to the nucleus, binds the androgen responsive elements (ARE), affects the transcription of androgen-regulated genes (e.g. prostate-specific antigen, PSA) and ultimately stimulates the proliferation and inhibits apoptosis of prostate cancer cells.
Many studies have reported that androgen receptor mutations and polymorphism are deeply involved in prostate cancer [7] and [8] . This receptor is encoded by AR gene, located on the X chromosome, at Xq11-12 [9] , which consists of 6 functional domains ''labeled A through F" [10] . The ligand binding domain (LBD) (domain E) represents the attachment site of androgens and has activation function-2 (AF2), which is responsible for agonist induced activity. Also, the LBD functions as a nuclear export signal [11] . Mutations in LBD were found to restrict the binding of testosterone or DHT to the receptor and subsequently impair AR mediated transactivation. The literature has reported unlimited number of genetic abnormalities in different domains of the AR gene. Most of these genetic abnormalities were detected in prostate cancer (PCa) patients. Also, the majority (79%) of mutations, identified in the LBD in PCa patients, were clustered to three discrete regions that influence the receptor activity [12] .
A few studies have investigated the genetic integrity of AR gene during the progression toward cancer, especially in patients with androgen insensitivity syndrome (AIS) and/or patients with prostate cancer. Hence, this work was designated to investigate the genetic integrity of LBD in patients with benign prostatic hyperplasia (BPH) and those who developed prostate cancer (PCa) compared to the constitutional restriction pattern.
Subjects and methods

Patient population and grouping
The study included 30 male patients. All subjects were selected from inpatient of the catheterization units of El-Hussein hospital, Al-Azhar University, and Shebin El-Kome hospital and from El-Mataria Institute. Samples were obtained after surgery under informed consent, following the regulations and approval of the ethics committee and in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments in humans. Patient's medical history and PSA levels were recorded with special attention to any associated medical problems. The inclusion criteria were benign prostatic hyperplasia (BPH) or prostate cancer (PCa). Patients were divided into two groups. Group I (n = 15) included patients with BPH, their ages ranged from 48 to 82 years (average ± SEM: 58.9 ± 2.59 years), whereas group II included 15 patients diagnosed with PCa, their ages ranged from 47 to 75 years (average ± slandered deviation: 61.8 ± 2.9 years) ( Table 1) .
Extraction of genomic DNA and exons amplification
Genomic DNA was extracted from tissues of BPH and PCa tumors using QlAmp DNA (GENELUTE) following the manufacturer's instruction. The DNA yield was measured at 260 nm and its integrity was tested by running onto 1.5% agarose gel. Exons 4-8 of the LBD were amplified using segment specific primer pairs ( Table 2 ). In each amplification, 100 ng/ll was amplified in a PCR mix containing 1X (5 ll of 10X buffer) (Stratagene), 0.2 mM each dNTP (2 ll dNTPs mix), 100 pmol/ll (2 ll) of each exon specific primers (Integrated DNA Technologies, USA) and 2.5 U (0.5 ll) Taq DNA polymerase (GENE KRAFT, Germany). The reaction mixture was brought to 50 ll with molecular biology grade water.
Reactions of exons 4/5 and 6 were subjected to a thermal cycling program consisting of initial denaturation at 94°C for 5 min, followed by 35 cycles of annealing at 55°C for 30 s, primer extension at 72°C for 40 s and denaturation at 94°C for 30 s followed by a single extension at 72°C for 5 min. For exons 7 and 8 amplification, reactions were subjected to a thermal cycling program consisting of initial denaturation step at 94°C for 5 min, followed by 35 cycles of annealing at 58°C for 40 s, primer extension at 72°C for 1 min and denaturation at 94°C for 30 s followed by a single extension step at 72°C for 10 min. At the end of the reaction, the amplification products (10 ll) resolved onto 2% agarose gel containing ethidium bromide for 30 min at 70 V, where DNA bands were visualized and photographed under a UV transilluminator.
Restriction analysis
Restriction analysis polymorphism of the LBD was undertaken using SmlI, HphI and Tsp45I (FERMINTASE, Germany). Each reaction included 1X of enzyme buffer, 5 ll of the targeted PCR product and 10 U of the restriction enzyme. Reactions were brought to 20 ll with water and incubated at 37°C for at least 4 h after which enzymes were inactivated by 3 ll of stop solution then 10 ll of the product was electrophoresed onto ethidium bromide-containing agarose gel (3%) and the restriction pattern was observed and photographed under UV. Restriction analysis of the wild type sequence of exons was performed using Restriction-Mapper, version 3 (http://restrictionmapper.org).
Data analysis
Prostate specific antigen (PSA) data were expressed as mean (±SEM). Statistical analysis was performed using GraphPad-Instat software (Graphpad, San Diego, CA, USA). The normal distribution of PSA data was tested by Kolmogorov-Smirnov (KS) normality test. Accordingly, the comparison between means was analyzed by the ANOVA test. P value less than 0.05 was considered significant.
Results
The study included 2 groups comprising BPH and PCa patients. Their diagnosis was confirmed by the histological analysis (Fig. 1) . The PSA data, obtained from patient's medical reports, indicated an increased PSA serum level in BPH patients, where it showed 3-5 fold increase compared to the normal PSA level. PCa patients, however, recorded normal to low PSA levels due to the radical prostatectomy they underwent (Table 1) . To investigate the integrity of the restriction pattern of LBD and its possible association with the progression from benign to invasive prostate cancer, we investigated the frequency of LBD polymorphisms, using SmlI, HphI and Tsp45I restriction enzymes in both premalignant and malignant tissues compared to the wild type restriction pattern identified by the Restriction-Mapper. The LBD consists of 894 pb, extends between nucleotides 2401 and 3294 and has 5 exons (4, 5, 6, 7 and 8) (Fig. 2) . (Fig. 3A) . The wild type sequence of exon 6 consists of 134 bp (nt: 2842-2974). This fragment contains a single recognition site for 17 restriction enzymes (including SmlI and Hph1), whereas Tsp45I has no recognition site along the exon sequence. Similar to the wild type, exon 6, in both groups, showed normal SmlI, Hph1 and Tsp45I restriction patterns (Fig. 3B ). Exon 7, in contrast, demonstrated the constitutional patterns of SmlI, Hph1 and Tsp45I only in BPH patients. However, Hph1 and Tsp45I revealed an abnormal pattern in 6 (40%) and 4 (26.7%) of the PCa patients, respectively (Fig. 3 , panels CII and CIII). A similar changing pattern was observed in exon 8. This fragment represents the C-terminal domain of the LBD. Its wild type sequence harbors a single recognition site for 17 enzymes and 2 sites for another 5 restriction enzymes. Other known restriction enzymes, however, are non-cutters (do not cleave this fragment). SmlI, Hph1 and Tsp45I restriction patterns were conserved in BPH patients (Fig. 3, panel D) . However, both Hph1 and Tsp45I in PCa patients (group II) showed abnormal restriction patterns in 3 (20%) and 2 (13.3%) in PCa patients, respectively. These patients have a single fragment of 288 bp, due to the elimination of the PhpI restriction site (Fig. 3, panel DII) . Also, they have 2 different abnormal banding patterns due to the elimination (or changing) of the Tsp45I restriction site (Fig. 3, panel DIII) .
Discussion
In this work the restriction analysis of SmlI, Tsp45I, and HphI in the LBD of human androgen receptor gene was used to investigate the association between the integrity of this domain and the progression of BPH into PCa. Such approach was previously used to investigate the relation between LBD StuI site polymorphism and baldness, where it was found that LBD StuI restriction site was detected in 98.1% of young bald men, in 92.3% of older bald men and in 76.6% of non-bald men [13] . Herein, we analyzed the restriction pattern of the LBD in both BPH and (PCa) patients. Many reasons stand behind the choice for the LBD including: (i) This domain is [14] . (iii) LBD represents the pocket into which the ligand fits. Consequently, mutations in this domain may affect the conformation of the hormone binding site [15] . (iv) Helix 12 of the LBD plays an important role in the interaction between the androgen receptor and many coactivators, such as Steroid Receptor Coactivator-1 (SRC-1) and antiestrogens, such as tamoxifen [16] . (v) LBD contains the AF-2 of the androgen receptor, which is considered one of the most important functions of the receptor. (vi) LBD contains some domains that represent the binding site for heat shock protein-90 (HSP-90), which maintains the receptor in the nonliganded form in the cytoplasm in absence of the ligand [17] . The approach used is based upon the restriction analysis of 4 fragments representing the entire AR-LBD. The investigated exons (4-8) range in size from 131 bp (exon 6) to 158 bp (exon 7). Exon 4/5 analysis did not show any SmlI, HphI and Tsp45I restriction polymorphism in both benign BPH and PCa patients. Similarly, the 3 sites were conserved in exon 6 derived from both BPH and PCa patients. The normal restriction patterns obtained in both exons 4/5 and 6 do not exclude the existence of point mutations away from the recognition sites of the 3 enzymes used. Previously point mutation (T to G, led to M807R substitution) was reported in exon 6. This mutation has induced complete androgen insensitivity in a patient with 46, XY karyotype and affected the AR transactivation function (Tables 3 and 4 ) [18] .
Exon 7 has kept its restriction integrity in BPH patients. However, HphI and Tsp45I site polymorphism was observed in some PCa patients. There genetic abnormalities are supported with the high number of mutations previously reported in exon 7 [19] . Similarly, BPH patients did not show Tsp45I resection polymorphism in exon 8, where Tsp45I did not cleave the amplified fragment (288 bp). The androgen receptor gene mutations database [20] , has reported tens of mutations along exon 8. Also, some reports identified Q919R mutation in a prostate cancer patient. This may explain the development of Tsp45I polymorphism in 13% of PCa patients. The observed fragment (150 bp) may indicate a newly developed restriction site due to point mutation(s). Moreover the wobbling, coding of an amino acid with more than one codon, Tsp45I site (GTSAC) may enhance the chance of the development of a new cleavage site. Clustering of these genetic alterations in the last C-terminal part of the receptor (exons 7 and 8) is translated as defects in testosterone binding to the receptor, coactivator interaction and transactivation function due to the localization of these functions along or in the C-terminal part of LBD (Fig. 2) . This may explain how prostate cancer is transformed and progresses from an androgen-dependent state to an androgen-independent state [21] . Although androgen deprivation therapy suppresses the AR activity and inhibits the growth of prostate cancers, such genetic alterations could be the reason of recurrence and the development of androgen independent progression to prostate cancer [22] .
Conclusion
The data obtained may present an example for the parallel association between the existence of restriction polymorphism and the progression of benign prostatic hyperplasia to prostate cancer. Although normal restriction analysis does not eliminate the possibility of mutations, this approach presents a simple and fast genetic based discrimination between benign hyperplasia and invasive prostate cancer.
